RARE
Ultragenyx Pharmaceutical Inc. NASDAQ$24.81
Pre-mkt
$25.07
+1.05%
Mkt Cap $2.4B
52w Low $18.29
27.1% of range
52w High $42.37
50d MA $22.55
200d MA $27.72
P/E (TTM)
-4.2x
EV/EBITDA
-6.2x
P/B
—
Debt/Equity
-15.9x
ROE
718.8%
P/FCF
-4.8x
RSI (14)
—
ATR (14)
—
Beta
0.25
50d MA
$22.55
200d MA
$27.72
Avg Volume
2.1M
About
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypop…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | AMC | -1.20 | -1.29 | -7.5% | 23.50 | -8.3% | -12.7% | -14.1% | -13.0% | -7.1% | -3.3% | — |
| Nov 4, 2025 | AMC | -1.23 | -1.81 | -47.2% | 32.46 | -11.0% | -1.8% | -4.7% | -5.6% | -1.6% | +2.4% | — |
| Aug 5, 2025 | AMC | -1.27 | -1.17 | +7.9% | 28.92 | -1.5% | -3.0% | -3.8% | -4.8% | -5.3% | -2.8% | — |
| May 6, 2025 | AMC | -1.54 | -1.57 | -1.9% | 35.06 | +1.7% | -4.7% | +2.6% | +0.1% | +2.9% | +1.0% | — |
| Feb 13, 2025 | AMC | -1.32 | -1.39 | -5.3% | 43.52 | +2.3% | -2.4% | +0.2% | +1.8% | +2.2% | -2.1% | — |
| Nov 5, 2024 | AMC | -1.45 | -1.40 | +3.4% | 52.18 | +0.7% | -3.2% | -3.4% | -3.5% | -2.8% | -8.3% | — |
| Aug 1, 2024 | AMC | -1.64 | -1.52 | +7.3% | 44.15 | +6.9% | +14.3% | +11.2% | +12.7% | +10.8% | +13.9% | — |
| May 2, 2024 | AMC | -1.72 | -2.03 | -18.0% | 43.20 | +3.9% | -1.0% | -0.4% | -2.9% | -3.8% | -4.6% | — |
| Feb 15, 2024 | AMC | -1.65 | -1.52 | +7.9% | 46.26 | +1.6% | +5.8% | +3.5% | +4.2% | +5.7% | +7.0% | — |
| Nov 2, 2023 | AMC | -2.08 | -2.23 | -7.2% | 36.60 | +0.5% | +6.1% | +3.3% | +4.0% | -0.9% | -4.5% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $54.46 | $54.04 | -0.8% | +0.6% | +0.4% | +0.7% | -1.2% | -2.6% |
| Oct 21 | TD Cowen | Maintains | Buy → Buy | — | $56.26 | $56.16 | -0.2% | -3.2% | -2.6% | -2.8% | -2.6% | -4.3% |
| Oct 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $55.55 | $55.58 | +0.1% | +1.7% | +0.0% | -3.4% | -3.2% | -5.6% |
| Sep 26 | RBC Capital | Maintains | Outperform → Outperform | — | $56.76 | $56.99 | +0.4% | -2.7% | -4.1% | -2.1% | -0.4% | -2.1% |
| Sep 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $58.78 | $58.78 | +0.0% | -0.1% | -2.1% | -2.2% | -3.4% | -6.1% |
| Sep 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $58.74 | $59.37 | +1.1% | +1.1% | -0.4% | -1.8% | +0.1% | +0.0% |
| Aug 5 | Barclays | Maintains | Overweight → Overweight | — | $50.47 | $46.96 | -7.0% | -2.8% | -1.4% | -3.0% | -0.4% | -0.9% |
| Aug 2 | Wells Fargo | Maintains | Overweight → Overweight | — | $44.15 | $47.20 | +6.9% | +14.3% | +11.2% | +12.7% | +10.8% | +13.9% |
| Aug 2 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $44.15 | $47.20 | +6.9% | +14.3% | +11.2% | +12.7% | +10.8% | +13.9% |
| Aug 2 | Goldman Sachs | Maintains | Buy → Buy | — | $44.15 | $47.20 | +6.9% | +14.3% | +11.2% | +12.7% | +10.8% | +13.9% |
Recent Filings
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Unilife's UX111 product received regulatory approval, positioning the company for commercial launch, but investors should monitor manufacturing execution risks and whether the product meets durability expectations in real-world use.
Apr 2
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
RARE's clinical trial for its gene therapy will measure muscle strength outcomes through 48 weeks, providing critical efficacy data that could support regulatory approval and significantly impact the stock's valuation trajectory.
Mar 30
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Rare Genomics' experimental OTC deficiency treatment demonstrated clinically meaningful improvements in 64-71% of patients at Week 24, substantially outperforming placebo, potentially supporting regulatory approval and market opportunity for this rare disease indication.
Mar 12
8-K · 8.01
!! High
Ultragenyx Pharmaceutical Inc. -- 8-K 8.01: Material Event / Announcement
Ultragenyx Pharmaceutical's gene therapy DTX401 received FDA priority review for GSD Ia treatment, with an approval decision expected by August 2026, potentially enabling a significant new revenue stream.
Feb 23
8-K
Ultragenyx Pharmaceutical Inc. -- 8-K Filing
Ultragenyx Pharmaceutical will record significant charges in early 2026 related to terminating UX143 manufacturing agreements, signaling a strategic shift in the company's pipeline or manufacturing priorities.
Feb 12
8-K · 8.01
!! High
Ultragenyx Pharmaceutical Inc. -- 8-K 8.01: Material Event / Announcement
Ultragenyx Pharmaceutical's UX111 gene therapy demonstrated durable biomarker improvements and functional benefits in trial results, supporting potential regulatory approval and market expansion for this rare disease treatment.
Feb 3
Data updated apr 26, 2026 9:54pm
· Source: massive.com